Chronic Hyperkalemia in Heart Failure | Maintaining GDMT
Chronic Hyperkalemia in Heart Failure | Maintaining GDMT
* Hyperkalemia is a common barrier to optimal RAASi/ARNI and MRA therapy, particularly in patients with CKD.
* Reducing or stopping these life-saving therapies because of hyperkalemia may compromise their cardiovascular benefits.
* Newer potassium binders: patiromer and sodium zirconium cyclosilicate (SZC) can be used to control persistent/recurrent hyperkalemia and may facilitate continuation or optimization of GDMT.
* Before chronic treatment, assess reversible causes: medications, potassium supplements, diet, and acidosis.
* * Monitor K⁺ and renal function; with SZC, also watch for edema due to its sodium content.
